Company Name
Immix Biopharma Inc
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN:
US45258H1068
CIK:
0001873835
CUSIP:
45258H106
Currency:
USD
Full Time Employees:
21
Phone:
310 651 8041
Website:
https://www.immixbio.com
Fiscal Year End:
December
IPO Date:
Dec 16, 2021
Description:
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.
Address:
11400 West Olympic Boulevard, Los Angeles, CA, United States, 90064